NCT00576537

Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

Phase ll Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Cedars-Sinai Medical Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This research is being determine whether vaccinations with your own immune cells called " dendritic cells " can activate your immune system to fight your brain tumor.

Detailed description

To become eligible for therapy the following criteria must be fulfilled: * No age or gender limit * Patients with atypical malignant brain tumors. * Must have a Karnofsky performance of at least 60% * Hematologic studies and chemistry profiles will be within the parameters of the protocol * Tumor specimen of adequate size to yield protein concentration, tumor lysate peptide must be generated in sufficient quantity and patient must have no prior sensitivity to the components of the dendritic cell vaccine. * Patients are excluded if they have systemic disease, presence of acute infection, known history of autoimmune disorder and pregnancy.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
BIOLOGICAL	Dendritic Cell Immunotherapy	Patients will receive four vaccines.

Timeline

• Start date: 2001-03-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2007-12-19
• Last updated: 2019-05-03

Locations

1 site across 1 country: United States